New research from Spherix Global Insights reveals that access barriers, not drug efficacy, restrict the use of Ardelyx's Xphozah for dialysis patients with hyperphosphatemia. Nephrologists say they would nearly triple Xphozah prescriptions if reimbursement and coverage obstacles were removed. However, physicians also overestimate how well phosphorus levels are controlled and how often combination therapies are used. As the Transitional Drug Add-on Payment Adjustment (TDAPA) ends in 2026, reimbursement changes may further impact phosphate-lowering therapy markets. The study highlights a gap between treatment potential and real-world use, with dietitians playing a key role in therapy decisions and gastrointestinal side effects affecting patient persistence on Xphozah.
Roamly, a specialty insurance provider under The Ride Platform, has launched its flagship office in London and appointed Dan Severin as Head of Global Mobility Insurance. Severin brings extensive experience from Bolt and other insurance firms, positi...
Anteriad released the 2026 B2B Healthcare Marketing Edge Report showing that healthcare marketers are growing faster and hitting goals more often than other B2B marketers, with 33% success versus 28%. Investments in paid search and digital audio are ...
Plug Power's stock price jumped 83% in the first five months of 2026, reflecting strong investor enthusiasm for hydrogen energy. However, by midyear, the stock gave back all those gains, returning to its earlier levels. This volatility highlights the...
RBC Capital reduced Boeing's price target to $265, suggesting a 24.76% upside from its current price despite a mixed earnings report. Boeing posted a strong free cash flow of $631 million but reported an adjusted loss of $0.76 per share, worse than e...
Associated Banc-Corp reported strong financial results for Q2 2026, with adjusted earnings of $0.73 per share beating estimates and net income rising 11% year-over-year to $120.7 million. The growth was driven by higher net interest and non-interest ...
